Takeda to collaborate with a US company to develop and manufacture a new corona vaccine 22:14 on August 7
Pharmaceutical giant Takeda Pharmaceutical Co., Ltd. announced that it will partner with an American biotechnology company to develop and manufacture a new coronavirus vaccine for Japan. Takeda will provide manufacturing technology from this company and will improve the production capacity of vaccines more than 250 million times a year.
According to the announcement, Takeda will partner with an American biotechnology company, Novabacs, which is engaged in research and development of next-generation vaccines, and will provide the technology for manufacturing the new coronavirus vaccine being developed by this company. I have reached a basic agreement to receive it.
Takeda will set up a production facility at a factory in Hikari City, Yamaguchi Prefecture, and will receive a 30.1 billion yen subsidy from the Ministry of Health, Labor and Welfare to develop, manufacture, and distribute vaccines for Japan.
The company is working to improve its vaccine production capacity for more than 250 million doses a year, and in the second half of next year it will be able to manufacture the first vaccine and obtain national approval.
This is the first time that Takeda has partnered with a company for a new coronavirus vaccine, and the company says it wants to contribute to the public health and health of the Japanese people.